Entrada Therapeutics
TRDA
56 hedge funds and large institutions have $390M invested in Entrada Therapeutics in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 12 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
8% more capital invested
Capital invested by funds: $361M → $390M (+$28.8M)
8% more funds holding
Funds holding: 52 → 56 (+4)
2.33% more ownership
Funds ownership: 75.24% → 77.57% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.5M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.99M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.21M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$7.16M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$2.89M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.85M |
| 4 |
Millennium Management
New York
|
-$2.47M |
| 5 |
Jane Street
New York
|
-$1.07M |
TRDA Hedge Fund Activity: Q2 2023 in Review
56 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q2 2023, worth a combined $390M — up 8% from $361M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TRDA positions and 12 closed out — a net gain of 4 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $16.4M. The largest seller was Redmile Group, cutting an estimated $7.16M.
- 56 institutional investors held Entrada Therapeutics (TRDA) as of Q2 2023, up from 52 in Q1 2023.
- Funds reported $390M of Entrada Therapeutics stock for Q2 2023, up 8% quarter-over-quarter.
- 16 funds opened new Entrada Therapeutics positions in Q2 2023 and 12 closed out, a net change of +4 holders.
- The largest Entrada Therapeutics buyer in Q2 2023 was BlackRock, an estimated $16.4M added.
- The largest Entrada Therapeutics seller in Q2 2023 was Redmile Group, an estimated $7.16M sold.
Based on aggregated 13F filings for Q2 2023.